Lorenzo Cosmi1, Francesco Liotta, Francesco Annunziato. 1. aDepartment of Experimental and Clinical Medicine, University of Florence bImmunology and Cell Therapy Unit cRegenerative Therapy Unit, AOU Careggi Hospital, Florence, Italy.
Abstract
PURPOSE OF REVIEW: Th17 lymphocytes are now widely believed to be critical for the regulation of various chronic immune diseases, including asthma and chronic obstructive pulmonary disease. In this review, we discuss the current understanding of the role of Th17 cells in the pathogenesis of different asthma phenotypes and chronic obstructive pulmonary disease. RECENT FINDINGS: It has been recently reported that Th17 cells and also a new population of Th17/Th2 cells accumulate in bronchoalveolar lavage fluid of asthmatic patients, and positively correlated with airway obstruction and steroid resistance. These patients often have steroid resistant severe asthma and a predominant bronchial neutrophilic inflammation. SUMMARY: Steroid resistant severe asthma with predominant bronchial neutrophilic inflammation could benefit from IL-17 targeted therapies. In this view, the definition of clinical phenotypes and inflammatory endotypes of asthma in each patient will be necessary for personalizing the therapeutic approach.
PURPOSE OF REVIEW: Th17 lymphocytes are now widely believed to be critical for the regulation of various chronic immune diseases, including asthma and chronic obstructive pulmonary disease. In this review, we discuss the current understanding of the role of Th17 cells in the pathogenesis of different asthma phenotypes and chronic obstructive pulmonary disease. RECENT FINDINGS: It has been recently reported that Th17 cells and also a new population of Th17/Th2 cells accumulate in bronchoalveolar lavage fluid of asthmatic patients, and positively correlated with airway obstruction and steroid resistance. These patients often have steroid resistant severe asthma and a predominant bronchial neutrophilic inflammation. SUMMARY:Steroid resistant severe asthma with predominant bronchial neutrophilic inflammation could benefit from IL-17 targeted therapies. In this view, the definition of clinical phenotypes and inflammatory endotypes of asthma in each patient will be necessary for personalizing the therapeutic approach.
Authors: Jill E Weatherhead; Paul Porter; Amy Coffey; Dana Haydel; Leroy Versteeg; Bin Zhan; Ana Clara Gazzinelli Guimarães; Ricardo Fujiwara; Ana M Jaramillo; Maria Elena Bottazzi; Peter J Hotez; David B Corry; Coreen M Beaumier Journal: Infect Immun Date: 2018-11-20 Impact factor: 3.441
Authors: Elizabeth H Mann; Tzer-Ren Ho; Paul E Pfeffer; Nick C Matthews; Elfy Chevretton; Ian Mudway; Frank J Kelly; Catherine M Hawrylowicz Journal: Am J Respir Cell Mol Biol Date: 2017-09 Impact factor: 6.914
Authors: Thomas Southworth; Sarah Mason; Alan Bell; Isabel Ramis; Marta Calbet; Anna Domenech; Neus Prats; Montserrat Miralpeix; Dave Singh Journal: Biomark Res Date: 2018-04-11
Authors: Anne C A Mudde; Willem S Lexmond; Richard S Blumberg; Samuel Nurko; Edda Fiebiger Journal: World Allergy Organ J Date: 2016-07-15 Impact factor: 4.084